QTL Biosystems has announced four new additions to its Lightspeed fluorescence-based kinase and protease assays: PKC-alpha (diabetes and leukemia screening), Akt-1 (cancer), Src (cancer), and p38-alpha (leukemia and lymphoma). QTL said the homogenous assays, which can be read with most commercially available fluorescence spectrometers and multiwell plate readers, are scalable from 96- to 3,456-well formats, and feature limits of detection in the picomolar range.
EMD Biosciences, a part of Merck KgaA’s Life Science and Analytics division, has released several new Signal Transduction Interactive Pathways on its website. The Interactive Pathways provide researchers with graphical tools that depict known interactions that occur in cell signaling and can affect disease development, EMD said. Clicking on a component of a pathway displays information about related EMD products, including antibodies, inhibitors, enzymes, proteins, enzyme substrates, and kits, the company said.